Naveris, Inc. is set to present new data at the 66th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in Washington, D.C., from September 29 – October 2, 2024, showcasing advances in precision surveillance for HPV-associated oropharyngeal cancer using the NavDx® test. The presentations will highlight the role of the NavDx test, a clinically validated circulating Tumor Tissue Modified Viral (TTMV®)-HPV DNA blood test, in the management of HPV-driven oropharyngeal cancers, with a focus on integration into radiation oncology practices.
NavDx Test in HPV-Driven Cancer Management
Barry M. Berger, M.D., Chief Medical Officer at Naveris, stated that ASTRO provides an ideal platform to demonstrate how the NavDx test is transforming care for patients with HPV-driven cancers. The presentations will emphasize the test's role in personalizing treatment, enhancing real-time surveillance, and improving patient outcomes in radiation oncology.
Key Presentations at ASTRO 2024
Several presentations will feature the NavDx test, including:
- Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial: Li Wang, M.D., Ph.D., and Steven Frank, M.D., from MD Anderson Cancer Center, will present a study analyzing over 1,000 blood samples. The study demonstrates that the NavDx test can identify patients at risk for treatment failure earlier than imaging, suggesting its potential as a robust biomarker to guide treatment intensity in HPV+ OPSCC.
- Integration of HPV ctDNA Testing into Clinical Practice for HPV+ OPSCC: An educational session moderated by John Lukens, M.D., with speakers from the University of Pennsylvania, Mayo Clinic, University of Michigan, and Mass General Brigham, will explore the use of HPV ctDNA testing in clinical practice for HPV+ OPSCC, incorporating the NavDx test as part of a broader discussion on using ctDNA for treatment guidance and monitoring.
- (Poster) The Impact of Circulating Tumor Human Papillomavirus (HPV) DNA Clearance Kinetics on Disease Outcomes during Chemoradiation: Sujith Baliga, M.D., and David M. Blakaj, M.D., Ph.D., from The Ohio State University, will present a study showing that changes in NavDx test results during treatment can predict outcomes. Rapid clearance indicates better control, while persistent positivity suggests higher risk, highlighting NavDx as a tool for adjusting radiation therapy intensity based on patient risk.
- (Poster) Tracking Circulating Tumor HPV DNA with Early Cessation of Radiotherapy in Oropharynx Cancer: Zubir Rentiya, M.D., MSc, and Charles McLaughlin, M.D., from the University of Virginia, will present a study showing that using mid-treatment NavDx test results to guide early cessation of radiotherapy led to excellent outcomes, with superior progression-free survival compared to patients completing the full course of treatment.
- (Poster) Comparative Performance of ctHPVDNA and Imaging Surveillance for Oropharyngeal Cancer Following Radiotherapy: Yifu Ding, M.D., Ph.D., and Walter A. Stokes, M.D., from Winship Cancer Institute of Emory University, will present a study finding that NavDx outperforms imaging in post-radiotherapy surveillance, with fewer false positives and higher specificity.
Naveris will be exhibiting at Booth #2037 to provide more information about NavDx and its impact on improving care for patients with HPV-driven cancers in radiation oncology.
